GlobeNewswire

Ovum Survey Finds NetSfere Among The Top 3 Most Widely Deployed Secure Enterprise Messaging Services

Dela

NetSfere is the third most used enterprise platform, clearly outpacing legacy enterprise communication vendors

 

CHICAGO, Feb. 20, 2018 (GLOBE NEWSWIRE) -- A report by Ovum, a market-leading research and consulting firm, commissioned by Infinite Convergence Solutions, a global leader in messaging and mobility solutions, finds that within just a few short years of launching, NetSfere is ranked as the third most used enterprise messaging service behind Skype Business and Cisco's Spark.

In addition to the need for a secure messaging service, the report shows enterprise demand for communication services that enable collaboration beyond messaging. NetSfere's combined HD voice, video and text capabilities - all preferred means of communication in one encrypted platform - validates its ranking among the top services for enterprises.

"With messaging services advancing into all-in-one communications platforms, there's a greater propensity for widespread business use - but also major security risks," said Anurag Lal, CEO and President of Infinite Convergence Solutions, creators of NetSfere. "NetSfere is widely successful because it brings together the ultimate combination of collaboration, productivity, security and compliance that is unmatched when compared to third-party consumer messaging services. We're extremely proud that NetSfere is among the top three enterprise messaging platforms, a clear indication that the well-established legacy platforms have been outpaced by enterprises' communication needs in the mobile era."

Ovum's report, "Secure Enterprise Messaging in the Age of the Chat App," proves a quick-growing need for reliable and secure enterprise messaging services. While most respondents use chat apps for one-to-one messaging for daily work tasks, about 60 percent also use it for group messaging, including one-to-one voice and video communications, and nearly 75 percent of respondents share confidential and non-confidential documents.

"Enterprises have a strict responsibility to ensure employees' communication is secure and confidential, especially those working in industries where communication records are required to be stored for auditing," said Pamela Clark-Dickson, Practice Leader of Ovum. "But our research shows that enterprises are allowing the use of consumer messaging apps that don't provide those vital security features."

The report finds that 65 percent of respondents are concerned about chat apps representing security loopholes and 50 percent are concerned about their inability to monitor communication. Despite enterprises' concerns over consumer messaging services, organizations have still allowed their usage. Sixty-seven percent of respondents allow employees to use consumer mobile messaging apps because they believe it is impossible to effectively block their usage.

In order to meet employees' demands for a simple-to-use, familiar messaging service, NetSfere delivers a similar look and functionality to mirror the popular consumer app experience, but adds the security and compliance features necessary for the workplace, including global cloud-based service availability, device-to-device encryption, location-based features and administrative controls. Built to meet a variety of industry-specific needs, NetSfere also offers regulatory compliances, such as SOX and HIPAA.

For more information about the study, please visit the website.

About Infinite Convergence Solutions
Infinite Convergence Solutions, Inc. provides next-generation messaging and mobility solutions to carriers and enterprises globally, including an Enterprise Messaging Services suite, secure messaging through its standalone service NetSfere (www.netsfere.com) and SMS, MMS and RCS solutions. The company's technology supports more than 400 million subscribers and over a trillion messages on an annual basis. Infinite Convergence Solutions is a subsidiary of Infinite Computer Solutions (BSE:533154) (NSE:INFINITE) with offices in the United States, Germany, India and Singapore.

About NetSfere
NetSfere is a secure enterprise messaging service from Infinite Convergence Solutions, Inc. NetSfere provides industry-leading security and message delivery capabilities, including global cloud-based service availability, device-to-device encryption, location-based features and administrative controls. The service leverages Infinite Convergence's experience in delivering mobility solutions to tier 1 mobile operators globally and technology that supports more than 400 million subscribers and over a trillion messages on an annual basis. NetSfere is also compliant with regulatory requirements, including the Health Insurance Portability and Accountability Act (HIPAA), Sarbanes-Oxley and others. For more information, visit www.netsfere.com.

About Ovum 
Ovum is a market-leading research and consulting firm focused on helping digital service providers and their technology partners thrive in the connected digital economy. Through its 150 analysts and consultants worldwide, it offers expert analysis and strategic insight across the IT, telecoms, and media industries. Founded in 1985, Ovum has one of the most experienced analyst teams in the industry and is a respected source of guidance for business leaders, CIOs, vendors, service providers, and regulators looking for comprehensive, accurate, and insightful market data, research, and consulting. With 23 offices across 6 continents, Ovum offers a truly global perspective on technology, communications, and media markets. It provides clients with insight, including workflow tools, forecasts, surveys, market assessments, technology audits, and opinion.

Ovum is part of the Business Intelligence Division of Informa PLC, a leading business intelligence, academic publishing, knowledge, and events group listed on the London Stock Exchange.

Contact
Christine Curtin
Uproar PR for Infinite Convergence 
ccurtin@uproarpr.com
(312) 878-4575 x242




This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Infinite Convergence Solutions via Globenewswire

Om

GlobeNewswire



Följ GlobeNewswire

Abonnera på våra pressmeddelanden.

Senaste pressmeddelandena från GlobeNewswire

Arcoma AB: Arcoma presenterar på Redeye Life Science Day den 21:a november16.11.2018 12:53Pressmeddelande

16 November Den 21 november presenterar Jesper Söderqvist, VD på Arcoma, den senaste utvecklingen i Arcoma på Haymarket by Scandic i Stockholm. Presentationen "Arcoma, ett tillväxtbolag i en växande marknad" hålls klockan 13:00 och kan följas i livesändning på redeye.se/live/lsday-2018. Presentationen kommer även i efterhand att finnas tillgänglig på www.redeye.se/live/ls-day-2018 samt på Bolagets sida i Redeye Universe (redeye.se/company/Arcoma) Om Arcoma Arcoma, med lång erfarenhet av branschen, är en ledande leverantör av integrerade digitala röntgensystem med hög kvalitet och avancerad teknik. Arcomas produkter erbjuder den senaste digitala bildtekniken kombinerat med tekniskt avancerade rörliga positioneringssystem, vilket tillsammans med ergonomisk skandinavisk design, erbjuder kunden kompletta, konfigurerbara och funktionella digitala röntgensystem. Bolagets produkter säljs via återförsäljare samt via OEM-kunder och det finns idag över 3 500 av Arcomas röntgensystem installerade

Iconovo: kundprojekt blir framflyttat tre till sex månader8.11.2018 15:45Pressmeddelande

Fortsatt arbete med ett av Iconovos pågående kundprojekt kommer att flyttas fram tre till sex månader. Projektet avser utveckling av produkt anpassad för kund som ska svara för produktion och marknadslansering. Det aktuella arbetet var planerat att ske under fjärde kvartalet men beräknas ske under nästa år, och detta påverkar Iconovos omsättning under 2018 negativt med cirka 2 miljoner kronor. Orsaken är att kunden har beslutat att genomföra en mindre klinisk studie för att verifiera produkten innan nästa steg tas vilken omfattar investeringar i betydande mångmiljonbelopp i produktionskapacitet, baserat på Iconovos utveckling. Studien görs för kundens egna räkning och är inte villkorad av tillsynsmyndigheter. "Detta påverkar vårt resultat på kort sikt, men det faktum att kunden har beslutat att göra en betydande investering i faktisk produktion betyder att vi med stor säkerhet kan se fram emot licensintäkter under en lång tidsrymd framöver i samband med att produkten lanseras på markna

Stillfront Group AB: Inbjudan till Stillfront Groups kvartalsrapport för tredje kvartalet 20187.11.2018 14:34Pressmeddelande

PRESSMEDDELANDE 7 november 2018 Inbjudan till Stillfront Groups kvartalsrapport för tredje kvartalet 2018 Stillfront Groups kvartalsrapport för det tredje kvartalet 2018 kommer att publiceras klockan 07.00 den 22 november 2018. En webbsänd telefonkonferens kommer att hållas klockan 10.00 samma dag där Jörgen Larsson, VD och Sten Wranne, CFO, kommenterar resultatet. Presentationen och rapporten kommer efter presentationen att finnas tillgänglig på www.stillfront.com Webbsändningen nås på adressen: https://tv.streamfabriken.com/stillfront-q3-2018 För att delta via telefon, vänligen ring: SE: +46 8 566 426 63 UK: +44 20 300 898 01 US: +1 8 557 532 235 FÖR YTTERLIGARE INFORMATION, VÄNLIGEN KONTAKTA: Sofia Wretman, IR Phone: +46 708 11 64 30 sofia@stillfront.com OM STILLFRONT Stillfront är en oberoende utvecklare, förläggare och distributör av digitala spel - med visionen att bli en ledande indie-spelutvecklare och förläggare. Stillfront är verksamt genom tio näst intill självständiga dotte

Stillfront Group AB: Invitation to Stillfront Group Q3 presentation7.11.2018 14:34Pressmeddelande

Invitation to Stillfront Group Q3 presentation Stillfront Group interim report for the third quarter 2018 will be published at 07.00 CET on 22 November 2018. A presentation of the report will be held the same day at 10.00 CET via telephone conference or audiocast where Jörgen Larsson, CEO and CFO Sten Wranne are to comment on the report. The presentation can be viewed live at https://tv.streamfabriken.com/stillfront-q3-2018 To participate via phone please call: SE: +46 8 566 426 63 UK: +44 20 300 898 01 US: +1 8 557 532 235 FOR FURTHER INFORMATION, PLEASE CONTACT: Sofia Wretman, IR Phone: +46 708 11 64 30 sofia@stillfront.com ABOUT STILLFRONT Stillfront is a group of independent creators, publishers and distributors of digital games - with a vision to become the leading group of indie game creators and publishers. Stillfront operates through ten near-autonomous subsidiaries: Bytro Labs in Germany, Coldwood Interactive in Sweden, Power Challenge in the UK and Sweden, Dorado Online Games

Modus Therapeutics announces FDA Acceptance of Sevuparin IND for the treatment of sickle cell disease7.11.2018 08:30Pressmeddelande

STOCKHOLM, November 7, 2018. Karolinska Development's portfolio company Modus Therapeutics announces today that the U.S Food & Drug Administration (FDA) has approved the company's Investigational New Drug (IND) application to initiate a Phase I clinical trial with subcutaneous sevuparin for the treatment of sickle cell disease (SCD) FDA has decided to accept Modus Therapeutics' IND application of sevuparin for the treatment of SCD. Sevuparin is an innovative, proprietary modified polysaccharide drug with anti-adhesive, anti-aggregate and anti-inflammatory effects due to its multimodal mechanism of action. It has the potential to restore blood flow and prevent further microvascular obstructions in children and adults with SCD. At present, sevuparin is being evaluated as an intravenous infusion in a Phase II study in SCD patients with ongoing painful crises (also called vaso occlusive crises, VOC). In order to broaden the clinical scope and utility of sevuparin in the treatment of SCD, t

Modus Therapeutics announces FDA Acceptance of Sevuparin IND for the treatment of sickle cell disease7.11.2018 08:30Pressmeddelande

STOCKHOLM, November 7, 2018. Karolinska Development's portfolio company Modus Therapeutics announces today that the U.S Food & Drug Administration (FDA) has approved the company's Investigational New Drug (IND) application to initiate a Phase I clinical trial with subcutaneous sevuparin for the treatment of sickle cell disease (SCD) FDA has decided to accept Modus Therapeutics' IND application of sevuparin for the treatment of SCD. Sevuparin is an innovative, proprietary modified polysaccharide drug with anti-adhesive, anti-aggregate and anti-inflammatory effects due to its multimodal mechanism of action. It has the potential to restore blood flow and prevent further microvascular obstructions in children and adults with SCD. At present, sevuparin is being evaluated as an intravenous infusion in a Phase II study in SCD patients with ongoing painful crises (also called vaso occlusive crises, VOC). In order to broaden the clinical scope and utility of sevuparin in the treatment of SCD, t

I vårt pressrum kan du läsa de senaste pressmeddelandena, få tillgång till pressmaterial och hitta kontaktinformation.

Besök vårt pressrum